- What changed in MIST news today?
- Milestone reports $963,000 in CARDAMYST revenue and targets 30% lower operating expenses: Milestone Pharmaceuticals reported $963,000 in third-quarter revenue, below the $1.14 million estimate, and a basic loss per share of $0.18. It expects cost-efficiency measures to cut operating expenses by about 30% and extend its cash runway into late 2028.
- Does Rallies summarize MIST news?
- Yes. Rallies summarizes MIST news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
- Is MIST research on Rallies investment advice?
- No. Rallies provides research, data, and educational context for MIST. It does not provide personalized investment advice.
